SeekingAlpha · Oct 14, 2026
Tectonic Therapeutic, Inc. (TECX) Presents at CureHHT 16thHHT International Scientific Conference - Slideshow
2026-10-14. The following slide deck was published by Tectonic Therapeutic, Inc.
TE
NASDAQ · TECX
Tectonic Therapeutic, Inc.
Healthcare · Biotechnology
$18.98
Up+$1.32 (+6.95%)
Updated Nov 4, 2026, 10:42 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 364.22M
- P/E ratio
- -5.41
- Dividend yield
- 0.00%
- 52-week range
- $18.54 – $39.53
- Volume
- 199.13K
- Avg. volume
- 513.83K
Price performance · TECX
TECX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
TECX closed at $18.98 after 21 trading sessions, down 15.31% for the selected period.
- Last close
- $18.98
- Period change
- -15.31%
- Period low
- $18.98
- Period high
- $23.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $19.13 | $19.74 | $18.76 | $18.98 | 199.13K |
| Nov 2, 2026 | $19.78 | $19.94 | $18.535 | $18.98 | 183.87K |
| Oct 30, 2026 | $20.51 | $20.51 | $19.56 | $19.78 | 146.26K |
| Oct 29, 2026 | $20.92 | $21.44 | $20.355 | $20.50 | 139.59K |
| Oct 28, 2026 | $20.12 | $20.77 | $19.99 | $20.56 | 215.89K |
| Oct 27, 2026 | $20.09 | $20.54 | $19.735 | $20.34 | 226.97K |
| Oct 26, 2026 | $20.00 | $20.5195 | $19.75 | $19.95 | 151.22K |
| Oct 23, 2026 | $21.03 | $22.31 | $19.8301 | $20.07 | 144.97K |
| Oct 22, 2026 | $21.86 | $22.275 | $20.97 | $21.09 | 251.38K |
| Oct 21, 2026 | $21.86 | $22.30 | $21.53 | $21.84 | 152.83K |
| Oct 20, 2026 | $21.22 | $22.44 | $20.99 | $21.825 | 144.52K |
| Oct 19, 2026 | $20.78 | $21.2999 | $20.45 | $21.15 | 202.97K |
| Oct 16, 2026 | $21.35 | $21.51 | $20.55 | $20.65 | 175.43K |
| Oct 15, 2026 | $21.08 | $21.5099 | $21.055 | $21.30 | 187.39K |
| Oct 14, 2026 | $21.22 | $21.745 | $20.6013 | $20.96 | 190.78K |
| Oct 13, 2026 | $22.23 | $22.38 | $21.02 | $21.31 | 164.02K |
| Oct 12, 2026 | $22.99 | $23.115 | $22.26 | $22.35 | 103.92K |
| Oct 9, 2026 | $22.74 | $23.61 | $22.74 | $23.33 | 110.71K |
| Oct 8, 2026 | $22.56 | $22.9599 | $21.585 | $22.75 | 167.7K |
| Oct 7, 2026 | $22.23 | $23.425 | $22.00 | $22.71 | 300.79K |
| Oct 6, 2026 | $23.15 | $23.27 | $21.83 | $22.41 | 200.94K |
Latest TECX news
The latest Smart Investors Daily articles mentioning TECX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TECX research
Overview
Company profile and research snapshot.
Company profile
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | Neutral | — |
| Aug 7, 2026 | Wells Fargo | Overweight | — |
| May 26, 2026 | Raymond James | Strong Buy | — |
| Apr 14, 2026 | Stifel | Buy | — |
| Jan 8, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 12, 2026
UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26
UBS analyst Alice Nettleton initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Neutral rating and announces Price Target of $26.
Yahoo · Sep 29, 2026
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteersCompany plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate a
Yahoo · Sep 10, 2026
Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare
On August 6, Tectonic Therapeutic (NASDAQ:TECX) reported second quarter results built around two clinical wins rather than sales figures, since this is a clinical stage biotech company with no products on the market yet. The headline news is that both of its lead programs hit their scheduled marks this year, and the company says it […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
